NCT01053845已完成1 期
Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain
University Hospital, Clermont-Ferrand2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2010年4月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Comparison of the amplitude of N2P2 waves between healthy volunteers and patients suffering of peripheral neuropathic pain.
研究概览
简要总结
Several studies showed that activity of down inhibitor bundle is weakened in different painful pathologies as the fibromyalgy or the trigeminal nevralgy.
The purpose of the protocol is to study the working of down inhibitor bundle at patients suffering of neuropathic pain.
详细描述
Prospective study with comparison groups
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •neuropathic patients group
- •Patient suffering of peripheral neuropathic pain
- •18 years old women or men at least
排除标准
- •• Healthy volunteers
- •18 years old women or men at least
结局指标
主要结局
Comparison of the amplitude of N2P2 waves between healthy volunteers and patients suffering of peripheral neuropathic pain.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
NSAIDs in Coronary Artery Disease PatientsCADNCT01402804Heinrich-Heine University, Duesseldorf85
Unknown
不适用
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity SyndromesFatigue Syndrome, ChronicArthritis, RheumatoidFibromyalgiaNCT01154647Vrije Universiteit Brussel70
终止
4 期
Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint ReplacementArthroplasty, Replacement, KneeNCT00895531University of Louisville75
尚未招募
不适用
International study on etiology of inhibitors in patients with a moderate or mild form of hemophilia A, influences of immunogenetic and hemophilia treatment factors.NL-OMON32171Academisch Medisch Centrum60
已完成
3 期
Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 DiabetesType 2 DiabetesNCT01822548Azienda Ospedaliero-Universitaria di Parma64